Uganda: U.S. Donates Experimental Antibody Treatment to Bolster Uganda's Fight Against Ebola
[Nile Post] The United States government has delivered an experimental antibody treatment for Ebola to Uganda's Ministry of Health, strengthening the country's preparedness amid an ongoing outbreak of Bundibugyo virus disease in neighbouring Democratic Republic of the Congo (DRC).
The United States government has sent an experimental Ebola antibody treatment to Uganda's Ministry of Health in response to the ongoing Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC). The vials of the experimental treatment, called MBP134, are held ready for immediate use should an Ebola case arise in Uganda.
Uganda currently has no active Ebola cases. However, health authorities are vigilant about the risk of cross-border transmission due to the ongoing DRC outbreak and the movement of people between the two countries. MBP134 is designed to recognize and neutralize Ebola virus particles, showing effectiveness against multiple Ebola species in laboratory tests.
It is not yet approved for commercial use and is available for compassionate use only while further clinical research is conducted. The donation aims to bolster Uganda's response capabilities if Ebola crosses the border. U.S. Chargé d'Affaires Mikael Cleverley emphasized that the donation helps Uganda prepare swiftly to act against potential Ebola transmission.
The U.S. has provided over $619 million in support for Ebola response efforts in the region, remaining the largest contributor to the regional response.
Written by urgent.news from AllAfrica's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
